288 related articles for article (PubMed ID: 10965223)
1. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes.
Keravis T; Komas N; Lugnier C
J Vasc Res; 2000; 37(4):235-49. PubMed ID: 10965223
[TBL] [Abstract][Full Text] [Related]
2. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.
Ashikaga T; Strada SJ; Thompson WJ
Biochem Pharmacol; 1997 Nov; 54(10):1071-9. PubMed ID: 9464449
[TBL] [Abstract][Full Text] [Related]
6. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
8. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
9. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel.
Lugnier C; Keravis T; Eckly-Michel A
J Physiol Pharmacol; 1999 Dec; 50(4):639-52. PubMed ID: 10639014
[TBL] [Abstract][Full Text] [Related]
10. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery.
Pauvert O; Salvail D; Rousseau E; Lugnier C; Marthan R; Savineau JP
Biochem Pharmacol; 2002 May; 63(9):1763-72. PubMed ID: 12007579
[TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.
Kaumann AJ; Galindo-Tovar A; Escudero E; Vargas ML
Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):421-30. PubMed ID: 19693491
[TBL] [Abstract][Full Text] [Related]
14. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.
Favot L; Keravis T; Holl V; Le Bec A; Lugnier C
Thromb Haemost; 2003 Aug; 90(2):334-43. PubMed ID: 12888882
[TBL] [Abstract][Full Text] [Related]
15. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.
Hambleton R; Krall J; Tikishvili E; Honeggar M; Ahmad F; Manganiello VC; Movsesian MA
J Biol Chem; 2005 Nov; 280(47):39168-74. PubMed ID: 16172121
[TBL] [Abstract][Full Text] [Related]
16. Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.
Mercapide J; Santiago E; Alberdi E; Martinez-Irujo JJ
Biochem Pharmacol; 1999 Nov; 58(10):1675-83. PubMed ID: 10535760
[TBL] [Abstract][Full Text] [Related]
17. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
Erdogan S; Houslay MD
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
19. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
[TBL] [Abstract][Full Text] [Related]
20. Endothelium-independent and endothelium-dependent vasorelaxation by a dichloromethane fraction from Anogeissus Leiocarpus (DC) Guill. Et Perr. (Combretaceae): possible involvement of cyclic nucleotide phosphodiesterase inhibition.
Belemnaba L; Ouédraogo S; Auger C; Chataigneau T; Traore A; Guissou IP; Lugnier C; Schini-Kerth VB; Bucher B
Afr J Tradit Complement Altern Med; 2013; 10(2):173-9. PubMed ID: 24146440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
